Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer’s disease
Business Wire•17/11/2026•16:45 ET
0
Key Highlights
- ➤Diranersen 60 mg twice-yearly slowed CDR-SB decline 38% at Week 96.
- ➤60 mg regimen produced a 1.09-point CDR-SB treatment difference at two years.
- ➤Clinical decline slowing increased across 5 of 6 measures versus Week 76.
- ➤Diranersen was generally well tolerated through two years, with no new safety signals.
- ➤Biogen reported broad tau reductions in tau PET, CSF p-tau181, and plasma p-tau217.
Expert Statements
Holly Kordasiewicz, Executive vice president and chief development officer, Ionis
“The diranersen data presented at CTAD underscore the potential of our RNA-targeted technology to achieve meaningful reductions in tau and reinforce the promise of tau-lowering as a therapeutic approach for people living with early Alzheimer’s disease”
Holly Kordasiewicz, Executive vice president and chief development officer, Ionis
“The sustained and deepening clinical benefits are encouraging and we are proud to partner with Biogen.”
Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer’s disease
- Diranersen slowed clinical decline by 38% on CDR-SB at two years (Week 96) with the 60 mg twice-yearly regimen, corresponding to a 1.09-point treatment difference -
Get started
Create a free account to read the full story.
